Cargando…
BRCA1 reversion mutation acquired after treatment identified by liquid biopsy
• Secondary, reversion mutations in BRCA genes can restore protein function. • Reversion mutations can underlie resistance to therapies such as PARP inhibitors. • Reversion mutations arise during the course of treatment.
Autores principales: | Mayor, Paul, Gay, Laurie M., Lele, Shashikant, Elvin, Julia A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496455/ https://www.ncbi.nlm.nih.gov/pubmed/28706968 http://dx.doi.org/10.1016/j.gore.2017.06.010 |
Ejemplares similares
-
BRCA2 Reversion Mutation Identified by Liquid Biopsy After Durable Response to FOLFIRINOX in BRCA2-Associated Pancreatic Cancer
por: Kondo, Tomohiro, et al.
Publicado: (2020) -
Concordance of acquired mutations between metastatic lesions and liquid biopsy in metastatic colorectal cancer
por: Taniguchi, Fumitaka, et al.
Publicado: (2021) -
Mechanisms of acquired resistance to afatinib clarified with liquid biopsy
por: Nakamura, Tomomi, et al.
Publicado: (2018) -
Photodynamic Therapy in Gynecologic Malignancies: A Review of the Roswell Park Cancer Institute Experience
por: Mayor, Paul C., et al.
Publicado: (2016) -
Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy
por: Jóri, Balázs, et al.
Publicado: (2022)